You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

Article info

Article menu
Immunotherapy biomarkers
Original research
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

Authors

  • April A N Rose Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, CanadaDepartment of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Susan M Armstrong Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • David Hogg Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Marcus O Butler Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, CanadaDepartment of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, CanadaTumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Samuel D Saibil Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, CanadaDepartment of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, CanadaTumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Diana P Arteaga Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, CanadaDepartment of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Thiago Pimentel Muniz Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, CanadaDepartment of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Deirdre Kelly Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, CanadaDepartment of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Danny Ghazarian Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, CanadaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Ian King Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, CanadaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Zaid Saeed Kamil Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, CanadaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Kendra Ross Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Anna Spreafico Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, CanadaDepartment of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, CanadaTumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles

Citation

Rose AAN, Armstrong SM, Hogg D, et al
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
Journal for ImmunoTherapy of Cancer 2021;9:e001642. doi: 10.1136/jitc-2020-001642
Online issue publication 
November 23, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.